Prognostic significance of CD44 expression in adenocarcinoma of the lung

M R Clarke, R J Landreneau, N M Resnick, R Crowley, G J Dougherty, D L Cooper, S A Yousem

Abstract
Aims—To determine whether expression of CD44 in neoplasia is associated with tumour grade, stage and prognosis.
Methods—The immunohistochemical expression of CD44 was evaluated using the mouse antihuman monoclonal antibody 3G12 which recognises regions shared by all CD44 isoforms to determine whether expression in formalin fixed, paraffin wax embedded tissue correlates with tumour grade, stage or survival in adenocarcinoma of the lung. Thirty one adenocarcinomas of the lung, 16 T2N0 and 15 T2N1, and their nodal metastases were studied.
Results—Of the 31 tumours, 25 were positive for the CD44 antigen. CD44 expression correlated with tumour grade, in that intense staining was seen only in moderately and/or poorly differentiated tumours. CD44 did not correlate with nodal status, tumour size, pleural invasion, angiolymphatic invasion, or host inflammatory response, but did correlate with survival. A median survival of 46 months was observed in patients with moderate to strong CD44 expression compared with 24 months for those with no or weak expression. Nine patients were alive without evidence of disease at a median follow up of 61 months. Six (66%) of these nine patients had strong CD44 expression. This contrasts with strong expression in only three (17%) of the 17 patients dying with a median survival of 28 months.
Conclusion—In primary adenocarcinoma of the lung loss of CD44 expression is associated with less favorable outcome and may indicate a more aggressive neoplasm. CD44 may be a useful prognostic marker in lung carcinoma.

Keywords: CD44, adhesion molecule, lung cancer.

CD44 is a transmembrane glycoprotein with multiple biological functions including cellular adhesion. This molecule was originally recognised in lymphocytes and haematopoietic cells and was shown to facilitate lymphocyte recirculation through adhesion to high endothelial venules and lymphocyte activation. The role of CD44 in cell–cell and cell–matrix binding has also been identified; CD44 is the principle cell surface receptor for hyaluronan and is also purported to be involved in adhesion to collagen, fibronectin and the cytoskeletal protein ankyrin. The CD44 molecule consists of a cytoplasmic portion, which may be involved in signal transduction, a transmembrane region and an extracellular component. The molecule is polymorphic and the gene, which has been mapped to the short arm of chromosome 11, encodes numerous isoforms, generated by molecular mechanisms of alternative splicing and post-translational modifications. The 80–90 kDa isofrom (CD44S) is expressed in haematopoietic cells and many other cell types and has been found to play a major role in tumour cell migration on hyaluronate coated substrates. CD44S also appears to play a role in tumour growth as demonstrated in studies by Sy et al in which lymphoma cells transfected with the CD44S isofrom showed greatly enhanced local tumour formation when injected into nude mice. The larger, 140–160 kDa epithelial isoforms (CD44E) are weakly expressed in normal epithelium and more strongly in carcinoma. A third class of CD44 isoforms encodes proteins of even larger size, the so-called “variant” isoforms (CD44V), expression of which, in certain rodent cell lines, has been found to confer metastatic potential to non-metastasising cell lines. Homologous sequences of these variants were subsequently found in human carcinoma cell lines from lung, breast, colon, and pancreas. Recently, CD44V expression was determined to be widely present throughout the body in benign tissues as well, principally in epithelial cells, and to be modulated by cytokines.

In studies on human breast and colon carcinomas, variant isoforms are preferentially expressed in neoplastic tissues compared with normal tissues. Associations have also been found between tumour stage and prognosis and variant isoform expression. CD44 expression in non-Hodgkin’s lymphoma is strongly associated with poor outcome, even in low grade lymphomas with small S phase fractions. This is theoretically due to the ability of CD44 positive lymphoma cells to gain access to endothelial cells within lymph nodes and to disseminate subsequently. Conversely, the CD44 gene has been found to be downregulated in neuroblastoma cell lines.

To date, several studies have reported the immunohistochemical expression of CD44 in carcinomas. Strong CD44 expression is associated with poor outcome in ductal carcinomas of the breast. A progressive increase in CD44 staining intensity was observed in gastric biopsy specimens progressing from normal to dysplasia to carcinoma, and appeared
CD44 expression in adenocarcinoma of the lung

M201

to be associated with poor outcome.30 By contrast, in Barrett’s oesophagus, strong CD44 staining was observed in non-dysplastic areas and was reduced in dysplasia and Barrett’s associated adenocarcinomas.31 These studies offer contradictory or equivocal roles of CD44 in these gastrointestinal tumours.

More recently, Penno et al32 reported the results of their analysis of CD44 expression in lung tumours and lung tumour cell lines. CD44 expression was present in the majority of non-small cell carcinomas studied, but was absent in the majority of the small cell carcinomas. Reverse transcription and polymerase chain reaction (PCR) amplification determined that CD44S, but not the variant isoforms, was present in these tumours. No correlation was found between CD44 expression and tumour grade, stage or clinical outcome.

In the present study we investigated the cellular expression of total CD44 in T2N0 and T2N1 adenocarcinomas of the lung to determine whether any diagnostic or prognostic associations could be made in these tumours. Given the association of CD44 with tumour growth,18 large T2 tumours were chosen for study to determine specifically whether any difference in expression of CD44 was present in those surgically resectable tumours which developed nodal metastases and those that did not.

Methods

Primary adenocarcinomas of the lung were sequentially selected from patients undergoing formal pulmonary resection between June 1981 and June 1991. Those patients from whom tissue blocks were not available were excluded. Tumours met pathological stage T2 criteria of tumour size greater than 3 cm located 2 cm or more distal to the carina, or of smaller size with visceral pleural invasion.34 Patients with metastases in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes were classified as having N1 tumours. Patients with N2 and N3 disease, and metastasis to mediastinal, scalene or supraclavicular lymph nodes were excluded from this study. All patients were stable with less than 5% weight loss prior to surgery, and surgery was the primary and only treatment in this group. The pulmonary carcinomas were studied for histological grade (well, moderate or poorly differentiated), the presence or absence of angiolymphatic invasion, host inflammatory response (graded minimal, mild, moderate, or marked), pleural invasion, and nodal metastases.

IMMUNOHISTOCHEMISTRY

Immunoperoxidase staining was performed on formalin fixed, paraffin wax embedded sections of primary tumours and sections of lymph node metastases using the avidin-biotin complex technique as previously reported.33 Mouse anti-human monoclonal antibody 3G12 directed against CD44 (Dr G Dougherty), which recognises regions shared by all CD44 isoforms and is known to block CD44 mediated cellular adherence to hyaluronan, was run at a dilution of 1 in 5. Antibodies which recognise specific variant isoforms are available; however, in our experience, adequate staining has not been obtained on archival formalin fixed, paraffin wax embedded sections, as used in this retrospective study. The secondary antibody consisted of biotinylated antimouse immunoglobulin (Vector, Burlingame, California, USA) at a dilution of 1 in 200. Slides were independently reviewed by three pathologists (MRC, DLC and SAY). Positive staining was graded on intensity (1+ to 2+) and on percentage of positively staining cells (1–24%, 25–49%, 50–74%, and 75–100%, corresponding to 1+ to 4+). A combined score of 0 to 6 was assigned. Tumours which were scored at 0 to 1 were classified as negative; those as 2 were weakly positive; those as 3 and 4 moderately positive; and those as 5 and 6 strongly positive. Staining in non-neoplastic lung showed strong staining in the basal cells of the bronchial mucosa, and in lymphocytes and fibroblasts of the bronchial submucosa. These elements provided a positive internal control in sections with negatively staining tumours.

STATISTICAL ANALYSIS

Clinical follow up was obtained by review of medical records, tumour registry data and phone calls to patients and families. Statistical tests performed consisted of Student’s t test for continuous variables, Wilcoxon’s rank sum test was used if the data were either skewed or variances were significantly different. The χ² test was used for dichotomous variables and Fisher’s exact test when expected frequencies were small. The Kaplan–Meier product-limit method of estimation was used to calculate survival curves. The log-rank test was used to test for differences in any survival curves constructed. Perioperative deaths were excluded from any analyses.

Results

Primary adenocarcinomas of the lung from 31 patients were studied. The clinical and pathological features are listed in table 1. Twenty-five (81%) of the 31 tumours were CD44 positive with 18 showing moderate or strong staining. CD44 staining in tumours of low histological grade showed a distinct, basement

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Clinical and pathological features of patient group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Feature</td>
<td>T2N0 (n=16)</td>
</tr>
<tr>
<td>Male/female</td>
<td>11/5</td>
</tr>
<tr>
<td>Age, mean (range) (years)</td>
<td>64 (51–90)</td>
</tr>
<tr>
<td>Tumour size, mean (range) (cm)</td>
<td>4.8 (3.3–6.5)</td>
</tr>
<tr>
<td>Histological grade</td>
<td>well</td>
</tr>
<tr>
<td></td>
<td>moderate</td>
</tr>
<tr>
<td></td>
<td>poor</td>
</tr>
<tr>
<td>Pleural invasion</td>
<td>6</td>
</tr>
<tr>
<td>Angiolymphatic invasion</td>
<td>negative</td>
</tr>
<tr>
<td></td>
<td>weak</td>
</tr>
<tr>
<td></td>
<td>moderate</td>
</tr>
<tr>
<td></td>
<td>strong</td>
</tr>
<tr>
<td>Total</td>
<td>12</td>
</tr>
<tr>
<td>Median survival (months)</td>
<td>48</td>
</tr>
</tbody>
</table>
Table 2  CD44 expression and tumour grade

<table>
<thead>
<tr>
<th>CD44 staining</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Weak</td>
</tr>
<tr>
<td>Intensity</td>
<td>0</td>
</tr>
<tr>
<td>Weak</td>
<td>2</td>
</tr>
<tr>
<td>Moderate</td>
<td>2</td>
</tr>
<tr>
<td>Strong</td>
<td>0</td>
</tr>
<tr>
<td>Total</td>
<td>4</td>
</tr>
</tbody>
</table>

and lateral membrane pattern (fig 1A), whereas strongly positive high grade tumours demonstrated a circumferential membranous pattern (fig 1B). The staining pattern in nodal metastases paralleled that seen in the primary tumour, although it was generally weaker. CD44 expression correlated with tumour grade in that intense staining was seen only in grade 2 and 3 tumours (table 2); grade 1 tumours showed no or weak staining. A progressive increase from grade 1 to grade 3 was not present, however. No association was found between CD44 expression and pathological features, such as tumour size, pleural invasion, angiolymphatic invasion, degree of host inflammatory response, or tumour stage.

Excluding two perioperative deaths, long term follow up was available for 29 patients with a median survival of 48 months in the T1N0 group (n=15) compared with 23 months for the T2N1 group (n=14) (p<0.07). In comparing CD44 expression with survival a positive association was observed, with a median survival of 46 months in the 16 patients (nine with T2N0 and seven with T2N1 disease) exhibiting moderate to strong expression compared with 24 months for the 13 patients (six with T2N0 and seven with T2N1 disease) with weak or no CD44 expression (p<0.03) (fig 2). Nine patients were alive without evidence of disease at a median follow up of 61 months. Six (40%) of the 15 patients with T2N0 and three (27%) of those with T2N1 disease were in this group. Six (66%) of these nine patients had strong CD44 expression, whereas strong expression was present in only three (17%) of 17 patients dying with a median survival of 28 months (p<0.02).

Discussion

Molecular studies have demonstrated an association between CD44 expression and poor prognosis in lymphomas, and variant isoform expression and stage and outcome in breast and colon carcinomas.24-28 This has stimulated interest in the potential application of measurement of CD44 expression as a prognostic indicator in other epithelial malignancies. Antibodies which recognise total CD44 in fixed tissues, but not the variant isoforms, are available.

In this study of subgroups of stage I and stage II lung adenocarcinomas, total CD44 expression was as predictive of survival as conventional staging. Loss of CD44 in this group was associated with a worse outcome. This conflicts with preliminary reports of increased CD44 expression and poor outcome in ductal adenocarcinomas of the breast and adenocarcinomas of the stomach.29 30 In breast tumours strong CD44 staining was more common in tumours of higher grade, as we observed, as well as in those with other aggressive histological features. In comparing mortality data on their patients with strong CD44 expression with those with weak expression, strong CD44 staining was associated with poor outcome in patients with ductal cancers and node positive cancers. No difference
CD44 expression in adenocarcinoma of the lung

Figure 2 Kaplan-Meier analysis of patient survival and CD44 expression. A median survival of 46 months was observed for the 16 (T2N0 = 9; T2N1 = 7) patients with moderate to strong cellular expression and 24 months for the 13 patients (T2N0 = 6; T2N1 = 7) with no or weak CD44 expression (p = 0.03) (log-rank test).

was seen, however, in long term survival. Our findings do correlate with those observed in Barrett’s dysplasia and Barrett’s associated oesophageal adenocarcinomas, although clinical follow up was not available in that report.32

Also, in transitional cell carcinoma of the urinary bladder, loss of CD44 expression was seen in high grade tumours compared with low grade tumours and was also lost in aneuploid versus diploid tumours.33 In a recent preliminary study of lung tumours the presence of CD44 in non-small cell carcinomas and its virtual absence in the more aggressive small cell carcinomas suggested an inverse relation between CD44 and metastatic potential in lung tumours.33 The authors speculated that if CD44–hyaluronan interactions anchor cells in one area, the loss of hyaluronate binding capacity of cells lacking CD44 might relieve the cells of restraint to hyaluronate-rich tissue and facilitate metastatic spread. Furthermore, loss of the CD44R isoform, which is capable of forming dimers with both CD44S and CD44R molecules, may also act to promote loss of tumour cellular adhesion, and thus tumour metastasis.32

In the present study associations cannot necessarily be made between total CD44 expression and variant expression. At this institution, preliminary studies on lung tumours and lung tumour cell lines using molecular techniques suggest that, unlike squamous cell carcinomas of the lung and adenocarcinomas from other sites, adenocarcinomas of the lung do not commonly express CD44v isoforms (D L Cooper, personal communication). Therefore, prognostic implications of CD44 expression in lung adenocarcinomas may relate more to loss of standard CD44, rather than acquisition of high molecular variants, as observed in other tumours. The loss of total CD44 expression in biologically aggressive tumours harkens to previous arguments that the defective binding of cells to the extracellular matrix permits increased mobility and metastatic potential in pulmonary adenocarcinomas. In invasion and metastasis models this loss of cell–cell adherence and cell–matrix adhesion facilitates cell mobility and spread.34 The results of this preliminary study provides support for this hypothesis.

The prognostic implications of total CD44 expression in lung tumours may be similar to that observed for cadherins, calcium dependent transmembrane cellular adhesion molecules also involved in homotypic cell–cell adhesion.35 Inhibition of cadherin mediated cellular adhesion was found to increase the invasive capacity of malignant epithelial cells.36 E-cadherin expression in breast and colon cancer has also been found to be inversely related to tumour grade.37,38 Furthermore, in colonic carcinoma, loss of E-cadherin expression was significantly associated with lymph node metastases.41

Correlations between total CD44 expression and variant isoform expression and tumour stage, grade and patient outcome are not well understood, and may differ between different tissue types and organs. The findings in this study suggest that in primary adenocarcinoma of the lung total CD44 expression may have prognostic significance and as such, its determination may be a useful component of a prognostic panel of tests. Loss of CD44 expression in these tumours appears to correlate with more aggressive neoplasms, possibly due to loss of cell–cell or cell–matrix adhesion interactions mediated by this molecule.

7 Belitsos PC, Hildreth JE, August JT. Homotypic cell aggregation induced by anti-CD44 (frag-1) monoclonal antibodies and related to CD44 (F(0.1)) expression. J Immunol 1990;144:1661–70.
14 Dougherty GJ, Lansdorp PM, Cooper DL, Humphries RK. Molecular cloning of CD44R1 and CD44R2, two novel isoforms of the human CD44 lymphocyte “homing” re.
M204

Clarke, Landreneau, Retsnick, Crowley, Dougherty, Cooper, et al

15 Scearston GR, Bell MV, Jackson DG, Cornelis FB, Gerth U, Bell JI. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Immunology 1992;89:12160-4.
19 Stamenkovic I, Amiot M, Pesando JM, Seed B. A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family. Cell 1989;56: 1057-62.